Biotech IV Monitor

DNLI — Denali Therapeutics Inc.

$3.7B market cap · 6 upcoming readouts tracked

Clinical trial readout dates for Denali Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts62 Phase 3
Market cap$3.7B
Cash & investments$1.01Bas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-03

Upcoming readouts

Phase 1/2 DNL593
Frontotemporal Dementia · NCT05262023
December 2026
Ongoing
Phase 2 BIIB122 225 mg
Parkinson Disease · NCT06602193
March 2027
Ongoing
Phase 2/3 tividenofusp alfa
Mucopolysaccharidosis II · NCT06075537
June 2027
Enrolling
Phase 2/3 tividenofusp alfa
Mucopolysaccharidosis II · NCT05371613
December 2027
Ongoing
Phase 1/2 tividenofusp alfa
Mucopolysaccharidosis II · NCT04251026
February 2031
Ongoing
Phase 1/2 DNL126
Mucopolysaccharidosis Type IIIA · NCT06181136
July 2032
Recruiting

Cash position

Denali Therapeutics Inc. reported $1.01B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). It reported net income of $70M for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-03

Companies working on similar indications

Discussion

No messages yet. If you follow DNLI, you can start the conversation.
Track DNLI in real time
See live implied volatility for DNLI and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on DNLI
Contact — questions or corrections about DNLI: dukeupt@gmail.com